key: cord-0807873-xzqhn0q7
authors: Jodłowski, Przemysław J.; Kurowski, Grzegorz; Kuterasiński, Łukasz; Sitarz, Maciej; Jeleń, Piotr; Jaśkowska, Jolanta; Kołodziej, Andrzej; Pajdak, Anna; Majka, Zbigniew; Boguszewska-Czubara, Anna
title: Cracking the Chloroquine Conundrum: The Application of Defective UiO-66 Metal–Organic Framework Materials to Prevent the Onset of Heart Defects—In Vivo and In Vitro
date: 2020-12-30
journal: ACS Appl Mater Interfaces
DOI: 10.1021/acsami.0c21508
sha: df0f5d8c0a80281a8f6282dea29119e063baf756
doc_id: 807873
cord_uid: xzqhn0q7

[Image: see text] In this study, we present a modulated synthesis nanocrystalline defective UiO-66 metal–organic framework as a potential chloroquine diphosphate (CQ) delivery system. Increasing the concentration of hydrochloric acid during the modulated synthesis resulted in a considerable increase of pore volume, which enhanced the CQ loading in CQ@UiO-66 composites. Drug release tests for CQ@UiO-66 composites have confirmed prolonged CQ release in comparison with pure CQ. In vivo tests on a Danio reiro model organism have revealed that CQ released from CQ@UiO-66 25% showed lower toxicity and fewer cardiotoxic effects manifested by cardiac malformations and arrhythmia in comparison to analogous doses of CQ. Cytotoxicity tests proved that the CQ loaded on the defective UiO-66 cargo resulted in increased viability of cardiac cells (H9C2) as compared to incubation with pure CQ. The experimental results presented here may be a step forward in the context of reducing the cardiotoxicity CQ.

Metal−organic frameworks, denoted MOF, have revolutionized the strategies of modern material engineering due to the high degree of freedom in the design of high specific surface area and well-defined structures with a vast number of possible applications. 1 Although these materials are a group of porous solids, metal−organic frameworks are currently under intense research in a wide range of applications including catalysis, 2−4 medical applications, 5,6 drug delivery, 7 gas adsorption and separation, 1 and sensing. 8 Among the numerous applications of metal−organic frameworks in a wide range of applications, the use of MOF as a drug delivery system (DDS) has been widely studied. The specific properties of MOFs, such as high surface area, well-defined channels, low cytotoxicity, and low biodegradability, make the use of MOFs as drug carriers subject to their appropriate modification during the synthesis or postsynthetic steps. 9−11 Of the numerous metal−organic frameworks with potential use as drug delivery systems, Zn-, Fe-, Zr-, and Mg-based metal−organic frameworks are being researched intensely due to their low cytotoxicity, high biodegradability, and high biocompatibility. 7,10,12−16 Among the numerous groups of possible MOFs with various topologies, the zirconium-based metal−organic framework UiO-66 (Universitetet i Oslo) composed of octahedron clusters [Zr 6 O 4 (OH) 4 ] and 1,4benzenedicarboxylic acid ligands meets the requirements for drug carriers. Due to its properties, such as high thermal and physical properties, high surface area, and a high degree of freedom in synthesis and postsynthesis, its potential for modification has attracted considerable attention in terms of its potential as a drug delivery carrier. 12−15 In the work by Jarai et al., 13 composite dexamethasone@UiO-66 and rhodamien@ UiO-66 were determined as novel drug delivery systems for pulmonary diseases. It was found that the modulated synthesis of 100 nm crystals of UiO-66 does not affect the aerodynamics of NPs in aerosols and has a negligible effect on drug loading. It must be also emphasized that composite UiO-66 samples revealed pH-dependent stability and high resistance in extracellular degradation. The in vitro cytotoxicity tests revealed low cytotoxicity of Zr-based MOFs and high tolerance in murine in vivo tests. Another example of modulated synthesis of UiO-66 was presented in the work by Laźaro et al. 12 In this work, dichloroacetic acid and hydrochloric acid were used as a modulator during the synthesis of defective UiO-66. The UiO-66 crystal synthesized by the addition of 10 equiv of CHCl 2 COOH and 1 equiv of HCl during the solvothermal synthesis allowed the synthesis of UiO-66 crystals with considerably increased contribution of pores >10 Å. The versatility of UiO-66 nanocrystals prepared in this way was confirmed by the increased loading of different drugs including alendronate (Al, 27.5 wt %), α-cyano-4-hydroxycinnamic acid (α-CHC, 2.0 wt %), 5-fluorouracil (5-FU, 1.2 wt %), and their mixed composites: 5-FU@ α-CHC/AL/DCA@UiO-66 (1.6, 1.6, and 21.3 wt % respectively). The defected UiO-66 composites loaded with four different drugs showed considerable breast cancer activity and selectivity. The drug release study of α-CHC@Zr-based MOFs was also presented in the work by Orellana-Tavra et al. 11 These authors reported that efficient drug release is not related to the crystalline or amorphous state of Zr-based MOFs but corresponds to the pore size distribution and the size of the guest molecules. Furthermore, an interesting result regarding the amount of α-CHC loaded to prepare Zr-MOF samples is related to the organic precursors used during the syntheses of the drug carriers. The highest α-CHC loading, 31 wt %, was achieved for the Zr-MOF prepared with the use terephthalic acid (BDC) as an organic linker dissolved in a solution of HCl and dimethylformamide (DMF) and also for samples where naphthalene-2,6-dicarboxylic acid or 4,40-biphenyl-dicarboxylic acid were used (α-CHC loadings of 14.8 and 20.3 wt %, respectively). The Zr-MOF samples prepared by the BDC derivatives including 2-bromoterephthalic acid (Br-BDC), 2nitroterephthalic acid, or 2-amino terephthalic acid were characterized by their low α-CHC loadings, in the range of 3−7 wt %. The preparation of composite 5-FU@UiO-66 was also presented in the work by Tai et al. 15 In this work, UiO-66 and UiO-66-NH 2 -derivatives were prepared in a continuous flow microreactor by varying the reactor residence time of the UiO-66 precursors. The prepared UiO-66 was loaded with 5-FU by soaking nanocrystalline UiO-66 in 10 mg/mL (10 mL) 5-FU followed by solvent removal via evaporation to obtain a 2 mL solution. The 5-FU@UiO-66 samples isolated by centrifugation revealed 27 wt % 5-FU loading.

The World Health Organization recently announced the global pandemic COVID-19 (Coronavirus Disease 2019) caused by the SARS-CoV-2 virus. Despite drawing wide interest from researchers from many scientific areas, the development and use of a vaccine and good antiviral drugs are strictly dependent on the guidelines for introducing new drugs to the market. So far, there is no confirmed and well-described therapy that could help to treat and prevent the rapid development of COVID-19. 17 Nevertheless, despite the lack of drugs to inhibit the development of the SARS-CoV-2 virus, lists of drugs with potential antiviral properties are created and simultaneously modified. In the literature, potential drugs including chloroquine and hydroxychloroquine, remdesivir, azithromycin, and adjunctive therapies including supplementation with vitamins and zinc have been proposed. 17−20 Due to the ongoing clinical trials and ever new data on the safe use of drugs in COVID-19 treatment, recommendations on the use individual drugs change dynamically. 21 Of those drugs showing potential antiviral activity against SARS-CoV-2, chloroquine and hydroxychloroquine may be interesting from the medical and chemical point of view. Despite the fact that the National Institutes of Health has recommended that chloroquine and hydroxychloroquine are not used in COVID-19 treatment except in cases of clinical trials and hospital treatment, 21 both drugs have been widely used in the treatment of malaria 22 and lupus erythematosus, 23 in anti-cancer therapy, 24 and for dermatological diseases. 23 Although high dosages of chloroquine and its derivatives could have side effects such as cardiac disturbances, neuromyotoxicity, hypertension, and cardiac arrhythmia, they are still under consideration for potential use and testing.

One possible way to reduce the undesirable side effects associated with the use of CQ and HCQ is to incorporate the drug into the MOF matrix to prolong its release into the organism. Since Horcajada's work 16 proposed the use of MOFs for controlled and prolonged drug delivery, a number of research groups have intensified work to develop biocompatible MOFs for medical purposes. So far, numerous literature reports have confirmed prolonged drug release for a variety of molecules and MOFs, including Ibuprofen@MIL-100 or MIL-101, 16 Oridonin@MOF-5, 25 Ibuprofen@HKUST-1, 26 Anet-hole@HKUST-1, 26 Guaicaol@HKUST-1, 26 DS@ZJU-802, 27 5-fluorouracil@HKUST-1, 28 and many others. The understanding of the mechanisms and the drug release rate is influenced by many factors such as the drug and MOF type, MOF structure, pH, and type of environment. In addition, due to the high microporosity and narrow pore size distribution, the choice of the drug incorporated into the MOF matrix is limited or MOF synthesis optimization has to be developed to obtain larger pores. 16 To address the above-mentioned limitations and keeping in mind that the potential use of chloroquine and its derivatives goes beyond the scope of this paper, the authors would instead seek to answer the following questions: (a) whether zirconiumbased metal−organic framework representative UiO-66 may be used as a drug carrier, (b) what is the CQ release profile from the prepared CQ@UiO-66 composites, and (c) how CQ release from the prepared CQ@UiO-66 composites influences heart cells in terms of cytotoxicity and cardiac arrhythmia.

Thus, the aim of this paper is to prepare and characterize defective UiO-66 metal−organic frameworks as potential drug carriers for chloroquine diphosphate. We also performed additional in vivo and in vitro experiments to compare the cytotoxicity and cardiotoxicity of CQ@UiO-66 with chloroquine diphosphate.

Materials. In this study, all chemicals used were of reagent grade and commercially available. They included zirconium(IV) chloride (Sigma-Aldrich), terephthalic acid (H 2 BDC, Sigma-Aldrich, 98%), hydrochloric acid (POOCH Poland), N,N-dimethylformamide (DMF, Chempur, Poland), and chloroquine diphosphate salt (CQ, Sigma-Aldrich, >96%, Figure S1A ).

Syntheses. A series of UiO-66 with varying defect concentrations was synthesized according to the method previously described in the literature, 29 with some modifications. The defect concentration in UiO-66 X samples (X, vol % HCl; 25, 50) was achieved by adding 10 or 20 mL of concentrated HCl acid (36−38%) to 2.53 mmol ZrCl 4 and subsequently adding DMF to achieve 40 mL of total solution. To obtain complete dissolution of MOF precursors, the mixture was then sonicated in an ultrasound bath for 30 min. In the next step, 2.53 mmol H 2 BDC was added to the mixture and the volume was adjusted to 80 mL total solution. The final mixture was then sonicated in an ultrasonic bath for 30 min and subsequently transferred to Teflon liners and placed in an oven at 120°C for 24 h. Finally, the asreceived samples were washed three times with fresh DMF and methanol and then centrifuged (4000 rpm, 10 min). The washed UiO-66 samples were then activated in a vacuum drier at 110°C overnight. The samples were denoted UiO-66 12.5% and UiO-66 25%. The reference UiO-66 sample ("ideal" UiO-66 structure; Figure  S1B ) was synthesized according to the procedure previously described elsewhere. 30 In brief, 1 mmol ZrCl 4 and 2 mmol H 2 BDC were dissolved in 6 mL of DMF and subsequently 0.16 mL of concentrated HCl was added to the mixture. To completely dissolve all reagents, the resulting mixture was sonicated in an ultrasonic bath for 30 min. The mixed solution was then placed in an oven at 220°C for 20 h. The washing and activation procedures were similar to those for UiO-66 X samples.

The chloroquine diphosphate (CQ; Figure S1A ) UiO-66 X composites were prepared by dissolving 100 mg of chloroquine diphosphate salt in 100 mL of deionized water and then mixing with activated UiO-66 X samples for 24 h. Subsequently, the as-received CQ@UiO-66 X samples were washed with deionized water, centrifuged (4000 rpm, 10 min), and dried in ambient conditions. The amount of chloroquine diphosphate loaded was determined by soaking CQ@UiO-66 X composites in deionized water for 24 h and subsequently sonicating in an ultrasonic bath for 1 h to destroy the MOF structure. The as-received suspension was centrifuged (4000 rpm, 20 min), and the chloroquine diphosphate loading was determined by UV−vis spectroscopy at 342 nm using an AvaSpec-ULS3648 high-resolution spectrometer equipped with a transmission cuvette holder CH-MP with signal enhancing mirrors CH-MP-EM and Optical Fibers OF-UV-600-50-SS (x2) and an Ocean Optics DH-2000-BAL UV−vis−NIR light source.

The chloroquine diphosphate composites were denoted CQ@UiO-66 X (X, vol % HCl; 25, 50). The detailed CQ loadings in prepared CQ@UiO-66 X samples are summarized in Table 1 .

Characterizations. Powder X-ray diffraction (PXRD) patterns of prepared UiO-66 samples and CQ@UiO-66 X composites were obtained on a PANalytical X'Pert Pro MPD diffractometer equipped with Cu Kα radiation operating at 30 mA and 40 kV. The PXRD diffraction patterns were collected in the 5−80°2θ range with a step of 0.033°. The theoretical PXRD pattern was generated in Mercury 2020.1.1 software and crystallographic information file (.cif) for UiO-66 MOF described elsewhere 31 (the .cif file is available free of charge in the Supporting Information of Øien et al. 31 available at https:// pubs.acs.org/doi/abs/10.1021/cg501386j).

The surface structure of the samples was determined by the volumetric low-pressure nitrogen adsorption (LPNA) method. An ASAP 2020 analyzer, which operates in the pressure range of 0−0.1 MPa, was used for this purpose. Before the tests, the samples were degassed at a pressure of 10 −4 Pa and a temperature of 393 K for a period of 12 h. Nitrogen was used as the adsorbate. The measurement was carried out in isothermal conditions at 77 K.

LPNA tests allowed determination of the multilayer surface area by the BET method (SSA BET ), the single-layer surface area by the Langmuir method (SSA L ), and the pore volume by the nonlocal density functional theory (NLDFT) method (V NLDFT ) dedicated to the cylindrical pores and the N 2 adsorbate. These calculations helped establish the effectiveness of the modification to create mesopores in the MOF samples. They made it possible to characterize the nature of the defects resulting from the modification.

The prepared UiO-66 samples and CQ@UiO-66 X samples were characterized by means of Fourier transform infrared (FTIR) spectroscopy using a Thermo Nicolet is10 spectrometer equipped with a mercury cadmium telluride (MCT) detector and attenuated total reflectance (ATR)-FTIR accessory. The spectra were taken in the 4000−650 cm −1 range at 4 cm −1 resolution by averaging 128 scans.

The Raman maps of crystalline chloroquine diphosphate (CQ) and CQ@UiO-66 composites were obtained using a Witec α 300M+ spectrometer equipped with a ZEISS 100× lens, 488 nm diode laser, and 600 grating. Mapping was performed on a 20 × 20 μm 2 spot with 80 measurement points × 80 lines with 1 s accumulation. A total of 6400 spectra were collected per map. Obtained data were normalized to the most intensive bandapprox. 1620 cm −1 , corresponding to UiO-66.

The scanning electron microscopy images were obtained using a Nova Nano SEM 300 FEI microscope with ×100k magnification.

Release Profiles. The chloroquine diphosphate release profiles from CQ@UiO-66 X were determined according to the procedure previously described in the work by Orellana-Tavra, 11 with some modifications. In brief, 10 mg of composite CQ@UiO-66 X samples were placed in dialysis bags (Spectra/Por 4 Dialysis Tubing, 12−14 kD MWCO) with a 40 mL total volume of phosphate-buffered saline (PBS, 10 mM, pH 7.4) solution. The release experiments were performed under thermostatic conditions at 37°C and stirred with a magnetic stirrer at 200 rpm. At specified times, 1 mL of PBS solution was taken for UV−vis analysis and replaced with fresh PBS. The amount of CQ released from CQ@UiO-66 X composites was monitored by UV−vis spectrometry as well as for total CQ loading determination experiments. Each drug release experiment was repeated three times.

In Vivo. To determine acute toxicity of chloroquine diphosphate, the fish embryo toxicity (FET) test was performed on zebrafish ( Danio rerio) according to OECD Test Guideline 236. Briefly, newly fertilized zebrafish eggs were exposed to CQ for a period of 96 h at concentrations ranging from 1 to 3000 μg/mL (1.96 μM−5.88 mM). The system applied in the experiment was static, as the changes of solution concentrations did not exceed the range of 20% of nominal concentration values.

The water used in embryo cultivation as well as to prepare the solutions was embryo culture medium (E3 solution: 5 mmol/L NaCl, 0.17 mmol/L KCl, 0.33 mmol/L CaCl 2 , and 0.33 mmol/L MgSO 4 , containing no methylene blue, with a pH value of about 7.2). The experiment was performed in 24-well plates, with five embryos per well, ten per group. Each plate was covered and kept in an incubator set at 28 ± 0.5°C under a light/dark period of 12/12 h. During the exposure period, the growth of the fertilized eggs was monitored every 24 h and four visual observations including coagulation of fertilized eggs, lack of somite formation, lack of detachment of the tailbud from the yolk sac, and lack of heartbeat were recorded as indicators of lethality.

Additionally, the heartbeat was measured to evaluate the potential cardiotoxicity of CQ. At the end of the exposure period (96 hpf hours postfertilization), acute toxicity was determined based on a positive outcome in any of the four visual observations recorded, and the LC 50 was calculated. Moreover, images of the fish from each group were taken at the final time point to monitor the occurrence of any developmental malformations. For the observations, a Discovery V8 Stereo optical microscope and Zeiss hardware were used.

Then, knowing the toxic range of CQ for the D. reiro larva, the same FET tests were performed for UiO-66 and CQ@UiO-66 X composites. The amounts of the compounds were the same and proportional to the amount of chloroquine diphosphate liberated from the composite. The four visual observations as indicators of lethality and heartbeats were recorded. According to Directive 2010/63/EU on protecting animals used for scientific purposes, zebrafish is considered self-feeding larval forms up to 120 h postfertilization (hpf), i.e., for the first 5 days of life, and is therefore not treated like animals; thus, ethical approval from the authorities is not required.

In Vitro. To evaluate cardiotoxicity of chloroquine diphosphate as well as UiO-66 and chloroquine diphosphate (CQ) UiO-66 X composites, the H9C2 (ATCC CRL-1446rat cardiomyoblast) cell line (a commercially available myogenic cell line derived from the embryonic rat heart ventricle) was used. The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% of fetal bovine serum (FBS), penicillin (100 U/mL), and streptomycin (100 μg/mL). The cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 . Every 3 days, the cells were fed and subcultured when they reached a confluence of approximately 80% to prevent cell differentiation.

For the experiments, cells between passages 7 and 20 were used. First, the H9C2 cells were seeded (4 × 10 5 cells/mL) on 96-well plates and incubated with chloroquine diphosphate for a period of 24 h in a concentration ranging from 0.1 to 3000 μg/mL (0.196 μM− 5.88 mM). Then, a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) test was performed to evaluate the viability of cells. IC 50 for CQ was determined.

Knowing the toxic range of CQ for the H9C2 cell line, a similar MTT test was performed for UiO-66 and CQ@UiO-66 X composites. The images were taken with the use of a Leica DMi1 microscope.

In this study, three ideal UiO-66, UiO-66 12.5%, and UiO-66 25% samples with varying defect concentrations and three corresponding chloroquine@UiO-66 composites were synthesized. The crystallinity of the prepared materials was determined by PXRD ( Figure 1 ). The PXRD patterns of prepared parent UiO-66 samples are in good agreement with the simulated PXRD pattern reported elsewhere. 32 It may be observed that, for all prepared samples, the characteristic PXRD patterns correspond to the FC topology. 32−34 The low-temperature N 2 sorption results are summarized in Table 1 and Figure 1 . According to IUPAC, 35 the prepared samples exhibited type-II isotherms. The sorption capacity in the prepared UiO-66 samples increased as the percentage of chloric acid used during the UiO-66-modulated synthesis route. The reference UiO-66 sample returned a sorption capacity value of 405.3 cm 3 /g STP. After modulated synthesis with 12.5 and 25% addition of HCl, the N 2 sorption capacity increased to values of 412.4 and 447.2 cm 3 /g STP, respectively. 36 The presence of 12.5 and 25 vol % concentrated HCl during the modulated synthesis supports the hypothesis of coexisting missing node and missing linker defects in the UiO-66 structure. 37 The resulting UiO-66 crystals represent a more open structure, 37 which is easily accessible for nitrogen during low-temperature nitrogen adsorption. Similarly, in the work by Katz et al., 38 the accelerating effect of concentrated HCl on the formation of UiO-66 was also observed. The UiO-66 crystals were formed in the vials containing HCl right after 120 min. Katz et al. postulated that the addition of concentrated HCl during synthesis supports the dissociation of linkers, which further accelerates node connections. It may be deduced that the modulated synthesis of UiO-66 resulted in an increase of both SSA BET and SSA L . The "defect-free" sample UiO-66 revealed a SSA BET equal to 1047.5 m 2 /g, which is close to the calculated 970 m 2 /g and experimental 1105 m 2 /g values. 38 The SSA BET values for defective UiO-66 samples prepared with the addition of HCl, UiO-66 12.5%, and UiO-66 25% gradually increase to 1110.0 and 1289.1 m 2 /g, respectively. The increasing SSA BET with increasing HCl concentration in modulated synthesis supports the "ideality" of the UiO-66 structure and the increasing detectability of UiO-66 12.5% and UiO-66 25% samples. Important information was provided by the volume of pores, exhibiting large differences in porosity ( Table 1 ). The micropore volume with diameters <0.6 nm determined by the NLDFT model was in the range of 0.112− 0.139 cm 3 /g, and the total pore volume increased from 0.490 cm 3 /g for ideal UiO-66 to a maximum of 0.615 cm 3 /g for UiO-66 25%. It is worth noting that the change in pore distribution from micropores to mesopores was accompanied by a significant increase in pore volume and a decrease in the SSA BET /V NLDFT ratio.

The ATR-FTIR spectra of crystalline CQ, parent UiO-66 X samples, and their CQ composites are presented in Figure 2 . The crystalline CQ exhibit a complex FTIR spectrum ( Figure   2A , Table S1 ) with characteristic vibrations at 3427 cm −1 that was attributed to NH stretching vibrations, 39 in the 3230− 2700 region with characteristic CH stretching from aromatic and aliphatic groups, 39,40 and in two characteristic regions, 1650−1200 and 1100−650 cm −1 . The bands appearing at 1610 and 1593 cm −1 are attributed to CC carbocyclic and heterocyclic stretching vibrations. The additional bands appearing at 1067 and 1000 cm −1 are attributed to P−O stretching vibrations. 39 The ATR-FTIR spectra of parent UiO-66 X samples are presented in Figure 2B as a zoomed region of 2000−700 cm −1 . This region exhibits characteristic carboxylate bands at 1580 and 1395 cm −1 , attributed to in-phase and outof-phase stretching vibrations. 29 In the UiO-66 fingerprint region 800−650 cm −1 , there are characteristic bands at 743, 705, and 675 cm −1 attributed to Zr−O modes. 29 It must be pointed out that the intensity of these bands decreases gradually with an increase of HCl concentration used during modulated synthesis. The gradual decrease of Zr−O bands indicates local symmetry changes in the Zr cluster. 29 Analysis of the ATR-FTIR spectra of CQ@UiO-66 X samples ( Figure  2C ) confirms the presence of CQ in prepared composites. The characteristic CQ vibrations are observed at approx. 1600 cm −1 and approx. 1000 cm −1 . Since the bands at around 1600 cm −1 are also present in parent UiO-66 X samples, the bands at 1000 cm −1 indicating the presence of P−O from the CQ salt were chosen as a CQ marker. Both bands are associated with CQ increase with increasing defect concentration in CQ@UiO-66 X composites. The increase of intensities of bands at 1067 and 1000 cm −1 correlates well with the determined CQ loadings determined by UV−vis spectroscopy ( Table 1 ). The parent UiO-66 sample revealed the lowest CQ loadings (1.94 ± 0.04 wt %) and the lowest characteristic CQ marker intensities. The composite samples based on defective UiO-66 12.5% and UiO-66 25% revealed CQ loadings equal to 13.26 ± 0.26 and 21.28 ± 0.40 wt %, respectively. Moreover, simultaneously with an increase of the CQ marker bands, the bands at approx. 1600 cm −1 (initially attributed to the carboxylate in-phase and outof-phase stretching vibrations) in fact originate from C−N vibrations from the quinoline ring. The considerable increase of these bands, together with band broadening, supports the presence of CQ inside the UiO-66 X pores. 7 Raman mapping (Figures 3 and S2−S5 and Table S1 ) was performed for composite CQ@UiO-66 X samples to determine the distribution and relative chloroquine diphosphate concentrations. It may be observed that, for the chloroquine diphosphate-deficient composite CQ@UiO-66, the Raman map ( Figure 3A ) and the total average Raman spectrum ( Figure 3D ) exhibit mainly UiO-66 characteristic bands at 1615, 1458, 1436, and 1143 cm −1 (cf . Table S1 ), corresponding to CC stretching, in phase OCO symmetric stretching and terephthalates rings breathing and benzoate ring deformation, 41 respectively. The marking band related to crystalline chloroquine diphosphate at 1373 cm −1 (ν(C−C)) was not detected at CQ@UiO-66 and becomes more evident with increasing CQ concentration in UiO-66 12.5% and UiO-66 25% composites (cf. Table 1 ). The increasing content of chloroquine diphosphate associated with increasing defect concentration in the prepared samples may be observed from Raman maps, where the maximum count on the Raman detector was observed ( Figure 3A−C) .

The morphologies of parent UiO-66 samples and CQ composites were determined with the use of scanning electron microscopy (Figures 4 and S6−S9) . The nanosize of the individual crystals was confirmed for the UiO-66 12.5% and UiO-66 25% samples. A tendency toward formation of agglomerated oval crystals was observed for UiO-66 12.5% and UiO-66 25% samples prepared with the HCl modulator, which is in good agreement with the results presented by Clark et al. 29 The careful choice of modulator type and its concentration to obtain the required defect concentration and crystal size may be observed when comparing the particle sizes and their morphologies for HCl-modulated synthesis presented in this paper and the HF-modulated synthesis of UiO-66 crystals reported by Han et al. 42 In that work, the UiO-66 crystal size increased from 500 nm for 1 equiv of HF used for modulated synthesis to 6 μm when 3 equiv of HF was used. The differences in particle size and geometry support the discussion on pKa of the modulator used during the synthesis of UiO-66 by Shearer et al. 43 They concluded that defect concentration and crystal growth are correlated with the acidity/pK a of the modulator used. Comparison of several modulators, including CH 3 COOH, HCOOH, CHF 2 COOH, and CF 3 COOH, leads to the conclusion that the defect concentration and SS BET increase with increasing acidity/pK a . Furthermore, the difference between the pK a of the modulator used and the MOF linker H 2 BDC (pK a = 3.5) has to be considered during the design of defective MOFs. Since the modulator competes for the carboxylate sites on the Zr clusters, the small difference between pK a of the modulator and H 2 BDC inhibits nucleation, which results in the promotion of crystal growth. The comparison between the pK a of modulators, such as HF (pK a = 3.1) and HCl (pK a < 1), and H 2 BDC (pK a = 3.51) would therefore suggest the formation of large, well-defined crystals, as reported by Han et al. 42 The incorporation of CQ into UiO-66 X samples does not affect the crystal morphology or particle sizes ( Figure  4C,D) .

The chloroquine diphosphate release profiles from CQ@ UiO-66, CQ@UiO-66 12.5%, and CQ@UiO-66 25% composites were performed in PBS solution with pH 7.4 at 37°C and monitored using UV−vis spectroscopy ( Figure 5 ).

The CQ release profile exhibits a strict correlation of the amount of chloroquine diphosphate release with the HCl concentration used for UiO-66-modulated synthesis. The release profile for CQ@UiO-66 for the first 1 h follows the release trend profile for crystalline chloroquine diphosphate, which supports the thesis that the CQ is located at the outer layer of the UiO-66 matrix. Nevertheless, it must be pointed out that, for CQ@UiO-66 12.5% and CQ@UiO-66 25% composites for the first 3 h, the CQ release profiles are almost identical. The CQ release profiles for the CQ@UiO-66 12.5% sample at 0.5 and 3 h are equal to 11.90 ± 0.3 and 46.47 ± 0.36 vs 10.35 ± 0.19 and 45.22 ± 1.42% for CQ@UiO-66 25%, respectively. The drug release inhibition may be observed at the sixth hour of the CQ release test, where the release value equals 83.08 ± 2.89% for CQ@UiO-66 12.5% CQ and this value reaches 66.66 ± 1.84% for CQ@UiO-66 25%. Considerable differences in CQ release profiles may also be observed in hours 6−10 of CQ release. In the 8th and 10th hours of CQ release, tested differences between released drugs between both composites were equal to 11 and 9%, respectively. Complete CQ release was achieved for CQ@ UiO-66 12.5% and CQ@UiO-66 25% samples after 26 h. The reference crystalline CQ achieved complete dissolution after 8h. The growing number of structural defects resulting from the increased volume of concentrated HCl used during modulated synthesis contributes to the adsorption of chloroquine inside the UiO-66 structure. As a consequence, the diffusion path of chloroquine diphosphate molecules from UiO-66 channels is extended, which results in a slower drug release (cf. CQ-UiO-66 25% HCl). Moreover, the influence of the interactions between open metal sites and chloroquine diphosphate molecules on the slower release of CQ cannot be excluded. However, the mechanism of the prolonged release of CQ from CQ@UiO-66 X composites is unknown, and its study goes beyond the aims of this paper and will be the subject of further research. According to the literature reports, the number and the type of defects in UiO-66 structures in the form of missing ligands and/or missing linkers correlate with the nature of the modulator used during the UiO-66 synthesis step. 33,44−50 Wu et al. 48 proposed the synthesis of defected UiO-66 using acetic acid as a modulator. Based on highresolution neutron powder diffraction measurements, the existence of the missing linker defects was pervasively present in the UiO-66 structure. As a consequence, a considerable increase in the pore volume (150% increase) and surface area (up to 60%) was observed. In the work by Vermoortele et al., 45 the combination of trifluoroacetic acid and hydrochloric acid was used to obtain defective UiO-66. The resulting materials exhibited better catalytic activity due to the presence of more open pores and uncoordinated zirconium atoms. Additionally, in the work by Liu et al., 37 the defect types in defect-free and defective UiO-66 prepared by the use of acetic acid as a modulator were compared using high-resolution transmission electron microscopy (HRTEM) and PXRD techniques. This proved the coexistence of missing nodes and missing linkers in the prepared samples. The authors concluded that the missing node defects could be observed in a small region of the sample, whereas missing linker defects were prevailing. Based on literature data, and having in mind that the structural defect analysis by the thermogravimetric analysis (TGA) method assumes the presence of missing linkers, 47 we can assume that, in our samples, missing linker and missing node defects may coexist at the same time. This hypothesis is supported by the considerable increase of surface area and total pore volume determined by low-temperature nitrogen adsorption. Moreover, a considerable increase in chloroquine diphosphate loading in defective UiO-66 composites (cf. Table 1 ) supports the presence of large cavities in the prepared samples.

Chloroquine and its analogue hydroxychloroquine were developed for the treatment and prophylaxis of malaria during the Second World War. In these times, effectiveness was the main criteria and drug safety was not considered important. 51 As safety issues became increasingly significant in the development of new drugs, chloroquine and hydroxychloroquine were found to affect the electrophysiological properties of the heart. They prolong the QT interval, which can cause heart rhythm problems (ventricular arrhythmias). Chloroquine binds to cardiac sodium, calcium, and inward rectifier potassium channels to cause long QT syndrome, QRS widening, and conduction abnormalities. Literature data report cardiac complications induced by long-term chloroquine or hydroxychloroquine use, mainly disorders in cardiac conduction leading to heart failure. 52 As there is growing interest in using these agents for the treatment of acute COVID-19 as well as for prophylaxis, the use of chloroquine and hydroxychloroquine is currently widespread globally. 51 Therefore, we focused on the evaluation of the cardiotoxic effects of CQ and possibilities to reduce its cardiotoxic side effects through the use of MOFs permitting a gradual release of the active substance, in turn allowing long-term delivery of the drug at a lower, safer concentration.

Zebrafish is an excellent model for evaluating toxicity and cardiotoxicity in drug discovery due to advantages such as optical transparency, rapid cardiovascular development, and low costs of experiments. 53 Moreover, according to Directive 2010/63/EU on protecting animals used for scientific purposes, they are considered as self-feeding larval forms up to 120 h postfertilization (hpf), i.e., for the first 5 days of life, and are therefore not treated like animals, which eliminates ethical problems when using them in experiments. Taking into consideration that cardiotoxicity damages the heart muscles and other cardiac tissues and disrupts the electrophysiology of the heart, resulting in an inability to pump adequate blood throughout the body, which may lead to cardiac muscle dysfunction, D. reiro is the perfect experimental model for the rapid and direct observation of the correct functioning of the heart. 54 Our preliminary study included an acute toxicity test (FETfish embryo test) for crystalline CQ, according to the modified OECD Test Guideline no. 236, to establish LD 50 (to 1253 μg/mL (2.46 mM)see the Supporting Information, Figure S10 ). Cardiotoxicity was evaluated for the embryos at 96 hpf by measuring the heart rate as an indicator of the arrhythmic potential of CQ. Concentrations from 150 to 3000 μg/mL were found to significantly decrease the heart rate value in comparison to the E3 control group ( Figure S10 ). The reduction in the number of heartbeats was proportional to the increase in CQ dose and probably resulted from irregular heartbeats. During the observations, we noted numerous shortand long-term interruptions, even up to 20 s, in the proper working of the heart (Supporting Information video recordings, Table S2 and Videos S1−S20). Moreover, slight changes in heart morphology (initial stage of cardiac edema) were noticed for CQ doses equal to 750 μg/mL and the above caused ( Figure S10 ).

Based on the results obtained for crystalline CQ, we were able to set the doses of UiO-66 and CQ@UiO-66 25% as 10, 5, 3.75, 2.5, and 1.25 mg/mL, which was equal to 2000, 1000, 750, 500, and 250 μg/mL pure CQ, respectively. For these doses, an FET toxicity test was performed, and heartbeats were measured and compared to CQ alone ( Figure 6 ). Our results revealed that the use of UiO-66 as a carrier for CQ-decreased general toxicity, measured as the mortality rate, by up to seven times (from 80.31 to 11.785%) for the CQ dose of 2000 μg/ mL. We also observed a reduction in cardiotoxicity measured as the heart rate and the occurrence of cardiac malformations. We found that heart rate was 1.2−1.7 times higher when CQ was applied from UiO-66 than in the pure crystalline form. Moreover, in visual microscopic observations, we did not notice any symptoms of cardiac edema in individuals subjected to CQ liberated from CQ@UiO-66 25% or parent UiO-66 alone ( Figure S11 ). We also performed visual monitoring of cardiac growth starting from the second day after fertilization (dpf, 48 hpf). The obtained data ( Figure S12 ) revealed that the first abnormalities in heart development were observed at 72 hpf in the group of fish receiving CQ at the highest doses: 750, 1000, and 2000 μg/mL. Neither CQ liberated from CQ@ UiO-66 25% nor UiO-66 alone exhibited abnormal heart growth and development, which proved the cardioprotective effect of the application of UiO-66 as a CQ carrier.

The next step of our study was to evaluate whether chloroquine diphosphate may exert a direct toxic effect on heart cells. Therefore, we performed a CQ cytotoxicity test on the H9C2 cell line (myoblast cells) (Figures S13 and S14) . Interestingly, the CQ dose for cells was found to be more than 62 times lower than CQ LD 50 for zebrafish embryos ( Figure  7) , which proved the direct cytotoxic effects of crystalline chloroquine diphosphate on cardiac cells. This seems to be obvious, as CQ is described as having a direct impact on cardiac sodium, calcium, and potassium channels, therefore affecting the electrophysiological properties of the heart. 55 After having determined the CQ cardiac toxicity profile, we decided to use 5, 1.25, 0.25, and 0.1 mg/ml UiO-66 and CQ@ UiO-66, which produce effective CQ concentrations equal to 1000, 250, 50, and 20 μg/mL, respectively (Figure 7) . We noticed an increase in the viability of cells of 35, 48, 40, and 10% when increasing doses of crystalline CQ were replaced by CQ@UiO-66 12.5% and of 43, 57, 53, and 17% when CQ@ UiO-66 25% was used. Thus, in the cellular study, we proved the direct cardiotoxic effects of CQ and the protective influence of UiO-66 by maintaining a lower, stable, and safe concentration of CQ for a longer period of time.

Although caution is warranted in new drug applications, lethal overdoses of CQ have been noted during the current pandemic. Therefore, MOFs are required to decrease the CQ toxicity and UiO-66 allows an effective CQ concentration to be maintained for longer.

The aim of this paper was to obtain efficient drug delivery systems based on the defective UiO-66 metal−organic framework. The UiO-66 defect optimization in the UiO-66 structure allowed the introduction of 20 wt % chloroquine diphosphate. The prepared CQ@UiO-66 X composites revealed prolonged chloroquine diphosphate release in PBS solution. In vitro (cellular) as well as in vivo (zebrafish) experiments demonstrated and confirmed the positive effect of MOF in the active dosing of CQ to avoid overdosing, which, according to the available literature, leads to serious complications, including sudden death from cardiac problems and torsades de pointes. Taking into consideration the relatively narrow therapeutic window of chloroquine diphosphate, characterized by multiple cases of overdose leading to death from hemodynamic collapse or ventricular arrhythmias, 56 we have proved the required positive effect of CQ@ UiO-66 X composites characterized by long-term slow CQ low dosing, which allows the required therapeutic concentration to be maintained while avoiding undesirable side effects. Thus, the study should be continued to include patients with cardiovascular comorbidities and diseases where arrhythmia risk is the greatest, especially as they are in the group at the highest risk of severe effects of COVID-19.

■ ASSOCIATED CONTENT * sı Supporting Information (University of Wrocław) for a fruitful discussion on structural defects in UiO-66. Low-temperature nitrogen adsorption studies have been financed by the Strata Mechanics Research Institute of the Polish Academy of Sciences as part of statutory projects.

UiO-66 25%, CQ@UiO-66 12.5%, and CQ@UiO-66 25%; CQ acute toxicity in the FET test (D. reiro in vivo model); comparison of visual observations of D. reiro embryos exposed to crystalline CQ, UiO-66, and CQ@ UiO-66; comparison of visual observations of cardiotoxicity of crystalline CQ, UiO-66 12.5%, and CQ@UiO-66 12.5% on the H9C2 cell line; visual monitoring of cardiac growth in D. reiro embryos exposed to crystalline CQ, UiO-66, and CQ@UiO-66; infrared and Raman characteristics for CQ and UiO-66; video recordings of heartbeats observations for CQ in D. reiro embryos at 96 hpf (PDF) Dose of CQ (μg/mL): 0control (AVI) Dose of CQ (μg/mL): 250CQ250 (AVI) Dose of CQ (μg/mL): 400CQ400 (AVI) Dose of CQ (μg/mL): 500CQ500 (AVI) Dose of CQ (μg/mL): 700CQ700 (AVI) Dose of CQ (μg/mL): 750CQ750 (AVI) Dose of CQ (μg/mL): 1000CQ1000 (AVI) Dose of CQ (μg/mL): 1500CQ1500 (AVI) Dose of CQ (μg/mL): 2000CQ2000 (AVI) Dose of CQ (μg/mL): 3000CQ3000 (AVI) Dose of CQ@UiO-66 25% (μg/mL): 250CQ250@ UiO-66 25% 1.25 mg (AVI) Dose of CQ (μg/mL): 500CQ500@UiO-66 25% 2.5 mg (AVI) Dose of CQ (μg/mL): 750CQ750@UiO-66 25% 3.75 mg (AVI) Dose of CQ (μg/mL): 1000CQ1000@UiO-66 25% 5 mg (AVI) Dose of CQ (μg/mL): 2000CQ2000@UiO-66 25% 10 mg (AVI) Dose of UiO-66 25% (mg/mL): 1.25UiO-66 25% 1.25 mg (AVI) Dose of UiO-66 25% (mg/mL): 2.5UiO-66 25% 2.5 mg (AVI) Dose of UiO-66 25% (mg/mL

The Chemistry of Metal-Organic Frameworks, 2 Volume Set: Synthesis, Characterization, and Applications; The Chemistry of Metal-organic Frameworks: Synthesis, Characterization, and Applications

Mixed-Metal Strategy on Metal-Organic Frameworks (MOFs) for Functionalities Expansion: Co Substitution Induces Aerobic Oxidation of Cyclohexene over Inactive Ni-MOF-74

High Quality and Scalable Continuous Flow Production of Metal-Organic Frameworks

MOF-74 over Structured Carriers for Cyclohexene Oxidation -Spectroscopic and Microscopic Characterisation. Microporous Mesoporous Mater

Zirconium-Based Metal−Organic Frameworks for the Removal of Protein-Bound Uremic Toxin from Human Serum Albumin

Metal−Organic-Framework-Derived Carbon Nanostructure Augmented Sonodynamic Cancer Therapy

Fe-MIL-100 as Drug Delivery System for Asthma and Chronic Obstructive Pulmonary Disease Treatment and Diagnosis

Ultrasonic Assisted Synthesis of a Tetrazine Functionalized MOF and Its Application in Colorimetric Detection of Phenylhydrazine

FA-PEG Decorated MOF Nanoparticles as a Targeted Drug Delivery System for Controlled Release of an

Zn-MOF-74 as PH-Responsive Drug-Delivery System of Arsenic Trioxide

Drug Delivery and Controlled Release from Biocompatible Metal-Organic Frameworks Using Mechanical Amorphization

Multivariate Modulation of the Zr MOF UiO-66 for Defect-Controlled Combination Anticancer Drug Delivery

Evaluating UiO-66 Metal-Organic Framework (MOF) Nanoparticles as Acid-Sensitive Carriers for Pulmonary Drug Delivery Applications

Selective Surface PEGylation of UiO-66 Nanoparticles for Enhanced Stability, Cell Uptake, and PH-Responsive Drug Delivery

Facile Preparation of UiO-66 Nanoparticles with Tunable Sizes in a Continuous Flow Microreactor and Its Application in Drug Delivery

Metal-Organic Frameworks as Efficient Materials for Drug Delivery

Does Zinc Supplementation Enhance the Clinical Efficacy of Chloroquine/Hydroxychloroquine to Win Todays Battle against COVID-19?

Chloroquine and Hydroxychloroquine as Available Weapons to Fight COVID-19

In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)

Chloroquine and Hydroxychloroquine in the Context of COVID-19. Drugs Context 2020, 9, 1−8. (21) National Institutes of Health. COVID-19 Treatment Guidelines Panel

Complex of Chloroquine: Synthesis, Characterization and Structural Properties

Janus Sword Actions of Chloroquine and Hydroxychloroquine against COVID-19

A Triphenylphosphonium-Functionalized Mitochondriotropic Nanocarrier for Efficient Co-Delivery of Doxorubicin and Chloroquine and Enhanced Antineoplastic Activity

Investigation of Metal-Organic Framework-5 (MOF-5) as an Antitumor Drug Oridonin Sustained Release Carrier

Controlled Release of Drug Molecules in Metal−Organic Framework Material HKUST-1

A Zirconium-Based Metal-Organic Framework with Encapsulated Anionic Drug for Uncommonly Controlled Oral Drug Delivery

Elucidating the Drug Release from Metal-Organic Framework Nanocomposites via in Situ Synchrotron Microspectroscopy and Theoretical Modeling

Highly Defective UiO-66 Materials for the Adsorptive Removal of Perfluorooctanesulfonate

Tuned to Perfection: Ironing out the Defects in Metal-Organic Framework UiO-66

Detailed Structure Analysis of Atomic Positions and Defects in Zirconium Metal-Organic Frameworks

Disclosing the Complex Structure of UiO-66 Metal Organic Framework: A Synergic Combination of Experiment and Theory

Ce or Hf) Employing 2,5-Pyridinedicarboxylic Acid as a Linker: Defect Chemistry, Framework Hydrophilisation and Sorption Properties

Engineering New Defective Phases of UiO Family Metal-Organic Frameworks with Water

Recommendations for the Characterization of Porous Solids

A Facile Synthesis of UiO-66, UiO-67 and Their Derivatives

Imaging Defects and Their Evolution in a Metal−Organic Framework at Sub-Unit-Cell Resolution

39) Balaji, J. Spectroscopic Investigation and Qualitative Analysis on Some Anti-Malarial Drugs Primaquine Phosphate and Chloroquine Phosphate

Complex of Chloroquine: Synthesis, Characterization and Structural Properties

Effect of Benzoic Acid as a Modulator in the Structure of UiO-66: An Experimental and Computational Study

Facile Synthesis of Morphology and Size-Controlled Zirconium Metal-Organic Framework UiO-66: The Role of Hydrofluoric Acid in Crystallization

Defect Engineering: Tuning the Porosity and Composition of the Metal-Organic Framework UiO-66 via Modulated Synthesis

Type Metal-Organic Frameworks by Intentional Creation of Defects: A Theoretical Rationalization

Supporting Information for Synthesis Modulation as a Tool To Increase the Catalytic Activity of Metal−Organic Frameworks: The Unique Case of UiO-66 (Zr)

Tackling the Defect Conundrum in UiO-66: A Mixed-Linker Approach to Engineering Missing Linker Defects

Tuning the Properties of Zr6O8 Nodes in the Metal Organic Framework UiO-66 by Selection of Node-Bound Ligands and Linkers

Unusual and Highly Tunable Missing-Linker Defects in Zirconium Metal-Organic Framework UiO-66 and Their Important Effects on Gas Adsorption

Free Energy of Ligand Removal in the Metal-Organic Framework UiO-66

Tailoring the Properties of UiO-66 through Defect Engineering: A Review

Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan

Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature

Zebrafish as an Emerging Model Organism to Study Angiogenesis in Development and Regeneration

Using Zebrafish for Investigating the Molecular Mechanisms of Drug-Induced Cardiotoxicity

Assessment of Multi-Ion Channel Block in a Phase I Randomized Study Design: Results of the CiPA Phase I ECG Biomarker Validation Study

The Arrhythmogenic Cardiotoxicity of the Quinoline and Structurally Related Antimalarial Drugs: A Systematic Review